Skip to content

Omeros OMER Shares (Diluted)

Discontinued — last reported Q2 '23

Shares (Diluted) at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
58.3M+36.5%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
24.7M+75.9%
Immunome logo
ImmunomeIMNM
113.1M+42.5%
Vor Biopharma logo
Vor BiopharmaVOR
43M+589%
Annexon logo
AnnexonANNX
194.2M+31.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
125.4M+27.4%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$775.86M+313%
P/S8.6×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: Omeros’s 10-Q, filed August 9, 2023, on SEC EDGAR. View the filing →

Ask your AI about Omeros's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's shares (diluted)?
Omeros (OMER) reported shares (diluted) of 62.8M in Q2 2023.
How has Omeros's shares (diluted) changed year-over-year?
Omeros's shares (diluted) increased by 0.2% year-over-year, from 62.7M to 62.8M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.